Abstract:T cells play a critical role in allograft rejection. T-cell activation requires antigen recognition by the T-cell receptor (TCR)/CD3 complex and costimulation of accessory receptors. Non-FcR-binding anti-CD3ε antibodies (Abs) produce immunosuppression without the toxicity associated with Fc-dependent activation (1). Non-FcR-binding anti-CD3ε Abs may induce T-cell anergy, skew the T-cell repertoire toward the Th2 phenotype, modulate the TCR, and block antigen recognition (1). We have found that a critical mechanism of immunosuppression by non-FcR-binding anti-CD3ε Abs is the induction of apoptosis in antigen-activated T cells (2). Among the costimulatory receptors on T cells, CD28 has a pivotal role in the initiation and maintenance of T-cell responses. In various transplant models, inhibition of CD28:B7 interactions by CTLA4-Ig resulted in immunosuppression (3). However, treatment with anti-CD28 Abs was more effective than CTLA4-Ig in the prevention of graft-versus-host disease in mice (4). Therefore, selective targeting of CD28 may be a better approach to achieve transplantation tolerance than blocking B7 molecules, the ligands for both CD28 and CTLA4, as CTLA4 is inhibitory for T-cell activation. Here we tested the hypothesis that combined treatment with non-FcR-binding anti-CD3ε plus anti-CD28 Abs leads to transplantation tolerance by affecting independent and complementary pathways of T cell activation. The experiments were performed in the context of a strong allogeneic MHC stimulation by transplanting skin grafts from BALB/c (H2d) onto C57BL/6 (H2b) mice. Recipients were treated with control Ab, anti-CD28 alone, non-FcR-binding anti-CD3ε alone, or anti-CD3ε plus anti-CD28. As shown in Figure 1A, treatment with anti-CD3 significantly prolonged graft survival compared to control or anti-CD28 treatment (P <0.0001, P <0.0001), whereas anti-CD28 by itself was modestly effective (P =0.002). The combination of anti-CD3ε plus anti-CD28 Abs was significantly more effective than either Ab alone (P =0.002, and P <0.0001), but transplantation tolerance did not develop. We suspected that failure to achieve graft tolerance could result from non-tolerant T cells developing from the thymus after stopping treatment. These T cells could recognize alloantigens and reject the skin graft. To test this hypothesis, we utilized thymectomized C57BL/6 mice as recipients. Treatment with anti-CD3ε plus anti-CD28 Abs significantly prolonged graft survival compared to control Ab (Fig. 1B), but the magnitude of the effect was not significantly different in normal or thymectomized recipients (P =0.5). Figure 1: Prolongation of murine skin allograft survival. Normal (A) or thymectomized (B) C57BL/6 mice were transplanted with full-thickness skin grafts from BALB/c donors. Recipients were intraperitoneally injected with the reagents indicated once every other day for a total of eight doses. The dose of anti-CD3ε and anti-CD28 Abs were 80 and 100 μg/mouse, respectively. The control Ab used was normal hamster IgG.We conclude that anti-CD3 and anti-CD28 Abs have additive immunosuppressive effects, but their combination does not induce tolerance to skin transplants. The failure of inducing transplantation tolerance with this treatment is not caused by the emergence of non-tolerant T cells from the host thymus, but may result from incomplete depletion of alloreactive T cells, lack of inducing T-cell unresponsiveness, and/or lack of generating regulatory T cells. Xue-Zhong Yu1 Yoshio Nitta2,3 Sasha J. Bidwell1 Claudio Anasetti1,4

Low-affinity CD8+ T cells provide interclonal help to high-affinity CD8+ T cells to augment alloimmunity

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

A High Frequency of CD8+CD28- T-suppressor Cells Contributes to Maintaining Stable Graft Function and Reducing Immunosuppressant Dosage after Liver Transplantation

Alloantigen Affinity and Cd4 Help Determine Severity of Graft-Versus-Host Disease Mediated by Cd8 Donor T Cells

A Given Number of Effector T Cells Can Only Destroy a Limited Number of Target Cells in Graft Rejection

Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance.

Inactivation Of T-Cell Receptor-Mediated Integrin Activation Prolongs Allograft Survival In Amap-Deficient Mice

Transfer of Regulatory T Cells Generated Ex Vivo Modifies Graft Rejection Through Induction of Tolerogenic CD4+CD25+ Cells in the Recipient

T follicular helper cells expansion in transplant recipients correlates with graft infiltration and adverse outcomes

Identification of a Highly Functional Effector CD8+ T Cell Program After Transplantation in Mice and Humans

ADDITIVE EFFECTS OF ANTI-CD3 AND ANTI-CD28 ON PROLONGATION OF ALLOGENEIC SKINGRAFT SURVIVAL

Homeostatic proliferation is a barrier to transplantation tolerance.

Role of CD4+ and CD8+ T cells in early and late acute rejection of small bowel allograft

CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection.

Heterogeneity in allospecific T cell function in transplant tolerant hosts determines susceptibility to rejection following infection

HLA topography enforces shared and convergent immunodominant B cell and antibody alloresponses in transplant recipients

Advances in T follicular helper and T follicular regulatory cells in transplantation immunity

Allostimulation leads to emergence of a human B cell population with increased expression of HLA class I antigen presentation-associated molecules and the immunoglobulin receptor FcRL5

High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function

High Frequencies of Cd62l(+) Naive Regulatory T Cells in Allografts Are Associated with A Low Risk of Acute Graft-Versus-Host Disease Following Unmanipulated Allogeneic Haematopoietic Stem Cell Transplantation

Specifically differentiated T cell subset promotes tumor immunity over fatal immunity